| Previous Close | 7.57 |
| Open | 7.67 |
| Volume | 86,938 |
| Avg. Volume (3M) | 278,975 |
| Market Cap | 160,674,208 |
| Price / Book | 0.880 |
| 52 Weeks Range | |
| Earnings Date | 10 Feb 2022 |
| Diluted EPS (TTM) | -3.47 |
| Total Debt/Equity (MRQ) | 0.08% |
| Current Ratio (MRQ) | 12.60 |
| Operating Cash Flow (TTM) | -100.89 M |
| Levered Free Cash Flow (TTM) | -59.45 M |
| Return on Assets (TTM) | -44.06% |
| Return on Equity (TTM) | -57.49% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Mixed |
| Biotechnology (Global) | Bearish | Mixed | |
| Stock | Cybin Inc. | - | - |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | -1.00 |
|
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 238.24% |
| % Held by Institutions | 41.95% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Deep Track Capital, Lp | 31 Dec 2024 | 1,529,987 |
| Rosalind Advisors, Inc. | 31 Dec 2024 | 810,918 |
| Acorn Capital Advisors, Llc | 31 Dec 2024 | 734,393 |
| Sphera Funds Management Ltd. | 31 Dec 2024 | 538,111 |
| Ikarian Capital, Llc | 31 Dec 2024 | 397,175 |
| Pale Fire Capital Se | 31 Dec 2024 | 60,912 |
| Knott David M Jr | 31 Dec 2024 | 60,446 |
| Advisorshares Investments Llc | 31 Dec 2024 | 50,651 |
| Fore Capital, Llc | 31 Dec 2024 | 31,421 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 10 Feb 2025 | Announcement | Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights |
| 15 Jan 2025 | Announcement | Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder |
| 13 Jan 2025 | Announcement | Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025 |
| 09 Jan 2025 | Announcement | Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |